Pharmacogenetics Research Clinic Centre for Addiction and Mental Health, 250 College Street, R 132, Toronto, ON, Canada.
Toronto Western Hospital, Toronto, ON, Canada.
Eur Arch Psychiatry Clin Neurosci. 2018 Feb;268(1):3-15. doi: 10.1007/s00406-017-0820-z. Epub 2017 Jun 17.
With the emergence of knowledge implicating the human gut microbiome in the development and regulation of several physiological systems, evidence has accumulated to suggest a role for the gut microbiome in psychiatric conditions and drug response. A complex relationship between the enteric nervous system, the gut microbiota and the central nervous system has been described which allows for the microbiota to influence and respond to a variety of behaviors and psychiatric conditions. Additionally, the use of pharmaceuticals may interact with and alter the microbiota to potentially contribute to adverse effects of the drug. The gut microbiota has been described in several psychiatric disorders including depression and anxiety, but only a few reports have discussed the role of the microbiome in schizophrenia. The following review examines the evidence surrounding the gut microbiota in behavior and psychiatric illness, the role of the microbiota in schizophrenia and the potential for antipsychotics to alter the gut microbiota and promote adverse metabolic events.
随着越来越多的知识表明人类肠道微生物组在几个生理系统的发育和调节中发挥作用，有证据表明肠道微生物组在精神疾病和药物反应中起作用。已经描述了肠神经系统、肠道微生物群和中枢神经系统之间的复杂关系，使微生物群能够影响和响应各种行为和精神疾病。此外，药物的使用可能会与微生物群相互作用并改变微生物群，从而可能导致药物的不良反应。肠道微生物群在几种精神疾病中都有描述，包括抑郁症和焦虑症，但只有少数报道讨论了微生物群在精神分裂症中的作用。以下综述检查了围绕行为和精神疾病中的肠道微生物群、微生物群在精神分裂症中的作用以及抗精神病药改变肠道微生物群和促进不良代谢事件的潜力的证据。
